PHARMACY

Rite Aid picks CaptureRx as 340B technology vendor

BY Alaric DeArment

CAMP HILL, Pa. — Rite Aid is teaming up with a new technology vendor for dispensing drugs under a special federal discount program, the company said Tuesday.

Rite Aid announced that it had selected CaptureRx as its preferred vendor and administrator in dispensing drugs under 340B, a Federal Public Health Service program that allows health centers and hospitals to purchase outpatient drugs for less than half of their cost on the commercial market.

"Rite Aid has long been committed to the health of the communities we serve," Rite Aid EVP pharmacy Robert Thompson said. "Each day, our pharmacists provide services and programs to help our patients live and stay well. Our relationship with CaptureRx is just another way we can improve overall health outcomes of those we serve every day."

The company said it had set up several pilot sites and would offer the 340B program nationwide later this year.

"We are delighted to welcome Rite Aid to our extensive network as we work together to offer better access to quality care to improve the well-being of the communities we serve," CaptureRx COO Edward Gilmartin said.

More information about the program is available here.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA grants priority review to J&J heart drug

BY Alaric DeArment

RARITAN, N.J. — The Food and Drug Administration has given priority review to a regulatory application from Johnson & Johnson for a drug designed to reduce the risk of complications from internal blood clots.

J&J’s Janssen Research & Development division announced that the FDA had given the designation to Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of certain types of heart attacks in patients with acute coronary syndrome, which 1.2 million Americans are diagnosed with every year.

The agency gives priority review to medicines that represent advances in care or provide a treatment where no adequate therapy exists, J&J said. The designation allows the FDA to finish reviewing an application for a drug in six months rather than the usual 10.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

SoloHealth appoints chief revenue officer

BY Allison Cerra

ATLANTA — A consumer-driven healthcare technology company has expanded its executive team to include a newly created position.

SoloHealth on Tuesday announced the appointment of Mike Griffin as its chief revenue officer, effective immediately. In his new role, Griffin will lead the company’s long-term revenue generation and oversee the strategic direction of sales and marketing. Prior to joining SoloHealth, Griffin served as EVP marketing and strategic development at EyeWonder, a provider of interactive digital advertising products.

The announcement comes as SoloHealth prepares for a national wide rollout of the SoloHealth Station, the company’s next-generation, consumer health screening kiosk.

"We are thrilled to have someone with Mike’s knowledge and strategic leadership experience join SoloHealth, especially as we ready ourselves for what promises to be a fast-growing and pivotal next 12 to 18 months for the company," SoloHealth founder and CEO Bart Foster said. "With Mike’s vast experience across numerous industries, as well as expertise in today’s digital advertising space and technologies, I’m confident that we will meet and succeed the lofty goals we’ve set for the company and the SoloHealth Station."


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES